Ginsenoside Rh1 eliminates the cytoprotective phenotype of human immunodeficiency virus type 1-transduced human macrophages by inhibiting the phosphorylation of pyruvate dehydrogenase lipoamide kinase isozyme 1

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 7, 2013, Pages 1088-1094

  Jeong, Jin Ju ^a   Kim, Baek ^b   Kim, Dong Hyun ^a  

^a Kyung Hee University   (South Korea)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Ginsenoside Rh1; Human immunodeficiency virus type 1; Macrophage

Indexed keywords

GINSENOSIDE; GINSENOSIDE RH 1; MAMMALIAN TARGET OF RAPAMYCIN; MILTEFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE B; PYRUVATE DEHYDROGENASE KINASE; PYRUVATE DEHYDROGENASE LIPOAMIDE KINASE ISOZYME 1; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CELL ASSAY; CELL PROTECTION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FETUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MACROPHAGE; NEUROPROTECTION; PHENOTYPE; PROTEIN EXPRESSION;

CELL LINE; CELL SURVIVAL; CYCLOHEXIMIDE; CYTOPROTECTION; GINSENOSIDES; HIV-1; HUMANS; LIPOPOLYSACCHARIDES; MACROPHAGES; MICROSCOPY, FLUORESCENCE; PANAX; PHOSPHORYLATION; PLANT ROOTS; PRIMARY CELL CULTURE; PROTEIN-SERINE-THREONINE KINASES; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84880436146     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00013     Document Type: Article

References (21)

1. Lucas A, Kim Y, Rivera-Pabon O, Chae S, Kim D-H, Kim B. Targeting the PI3K/Akt cell survival pathway to induce cell death of HIV-1 infected macrophages with alkylphospholipid compounds. PLoS ONE, 5, e13121 (2010).
2. Chugh P, Fan S, Planelles V, Maggirwar SB, Dewhurst S, Kim B. Infection of human immunodeficiency virus and intracellular viral Tat protein exert a pro-survival effect in a human microglial cell line. J. Mol. Biol., 366, 67-81 (2007).
3. Chugh P, Bradel-Tretheway B, Monteiro-Filho CM, Planelles V, Maggirwar SB, Dewhurst S, Kim B. Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy. Retrovirology, 5, 11 (2008).
4. Koenig S, Gendelman HE, Orenstein JM, Dal Canto MC, Pezeshkpour GH, Yungbluth M, Janotta F, Aksamit A, Martin MA, Fauci AS. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science, 233, 1089-1093 (1986).
5. Cosenza MA, Zhao ML, Lee SC. HIV-1 expression protects macrophages and microglia from apoptotic death. Neuropathol. Appl. Neurobiol., 30, 478-490 (2004).
6. Gras G, Kaul M. Molecular mechanisms of neuroinvasion by monocytes-macrophages in HIV-1 infection. Retrovirology, 7, 30 (2010).
7. Irish BP, Khan ZK, Jain P, Nonnemacher MR, Pirrone V, Rahman S, Rajagopalan N, Suchitra JB, Mostoller K, Wigdahl B. Molecular mechanisms of neurodegenerative diseases induced by human retroviruses: A review. Am. J. Infect. Dis., 5, 231-258 (2009).
8. Kim DH. Chemical Diversity of Panax ginseng, Panax quinquifolium, and Panax notoginseng. J. Ginseng Res., 36, 1-15 (2012).
9. Kaneko H, Nakanishi K. Proof of the mysterious efficacy of ginseng: basic and clinical trials: clinical effects of medical ginseng, korean red ginseng: specifically, its anti-stress action for prevention of disease. J. Pharmacol. Sci., 95, 158-162 (2004).
10. Akao T, Kida H, Kanaoka M, Hattori M, Kobashi K. Intestinal bacterial hydrolysis is required for the appearance of compound K in rat plasma after oral administration of ginsenoside Rb1 from Panax ginseng. J. Pharm. Pharmacol., 50, 1155-1160 (1998).
11. Lee J, Lee E, Kim D, Lee J, Yoo J, Koh B. Studies on absorption, distribution and metabolism of ginseng in humans after oral administration. J. Ethnopharmacol., 122, 143-148 (2009).
12. Tawab MA, Bahr U, Karas M, Wurglics M, Schubert-Zsilavecz M. Degradation of ginsenosides in humans after oral administration. Drug Metab. Dispos., 31, 1065-1071 (2003).
13. Bae EA, Shin JE, Kim DH. Metabolism of ginsenoside Re by human intestinal microflora and its estrogenic effect. Biol. Pharm. Bull., 28, 1903-1908 (2005).
14. Joh EH, Lee IA, Jung IH, Kim DH. Ginsenoside Rb1 and its metabolite compound K inhibit IRAK-1 activation -The key step of inflammation. Biochem. Pharmacol., 82, 278-286 (2011).
15. Shin YW, Bae EA, Kim SS, Lee YC, Lee BY, Kim DH. The effects of ginsenoside Re and its metabolite, ginsenoside Rh1, on 12-Otetradecanoylphorbol 13-acetate-and oxazolone-induced mouse dermatitis models. Planta Med., 72, 376-378 (2006).
16. Cho YK, Jung YS, Sung H, Sim MK, Kim YK. High frequency of gross deletions in 5' LTR/gag and nef genes in patients infected with CRF02-AG of HIV type 1 who survived for over 20 years: an association with Korean red ginseng. AIDS Res. Hum. Retroviruses, 25, 535-541 (2009).
17. Kim Y, Hollenbaugh JA, Kim DH, Kim B. Novel PI3K/Akt inhibitors screened by the cytoprotective function of human immunodeficiency virus type 1 Tat. PLoS ONE, 6, e21781 (2011).
18. Diamond TL, Roshal M, Jamburuthugoda VK, Reynolds HM, Merriam AR, Lee KY, Balakrishnan M, Bambara RA, Planelles V, Dewhurst S, Kim B. Macrophage tropism of HIV-1 depends on efficient cellular dNTP utilization by reverse transcriptase. J. Biol. Chem., 279, 51545-51553 (2004).
19. Bhattacharya SK, Sinha PK, Sundar S, Thakur CP, Jha TK, Pandey K, Das VR, Kumar N, Lal C, Verma N, Singh VP, Ranjan A, Verma RB, Anders G, Sindermann H, Ganguly NK. Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J. Infect. Dis., 196, 591-598 (2007).
20. Hernández-Campos A, Velázquez-Martínez I, Castillo R, López-Vallejo F, Jia P, Yu Y, Giulianotti MA, Medina-Franco JL. Docking of protein kinase B inhibitors: implications in the structure-based optimization of a novel scaffold. Chem. Biol. Drug Des., 76, 269-276 (2010).
21. Kim D, Sun M, He L, Zhou QH, Chen J, Sun XM, Bepler G, Sebti SM, Cheng JQ. A small molecule inhibits Akt through direct binding to Akt and preventing Akt membrane translocation. J. Biol. Chem., 285, 8383-8394 (2010).